New Delhi: Eli Lilly has officially introduced Mounjaro (tirzepatide) in India, marking a major milestone in diabetes and weight-loss treatment. The drug, which has seen tremendous global demand, is priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for a 5 mg vial—significantly lower than its US price of $1,000-$1,200 per month.

Mounjaro is a once-weekly injectable drug that works by activating both GIP and GLP-1 hormone receptors, regulating blood sugar and reducing appetite. Clinical trials showed that patients on the highest dose lost an average of 21.8 kg over 72 weeks, making it one of the most effective weight-loss drugs available.

The launch comes at a time when India faces a rising obesity and diabetes crisis, with over 101 million diabetics and nearly 100 million people affected by obesity. Experts say Mounjaro could be a game-changer in metabolic health management, providing an alternative to Novo Nordisk’s Rybelsus (oral semaglutide), which currently dominates the Indian anti-obesity market.

The GLP-1 drug market in India has surged from ₹137 crore in 2020 to ₹535 crore in 2024, reflecting growing demand for medical weight-loss solutions. While Novo Nordisk’s injectable semaglutide (Ozempic, Wegovy) has not yet been launched in India, it is expected by 2026, increasing competition in the sector.

Despite its effectiveness, Mounjaro is a prescription-only drug and must be used under strict medical supervision. Experts caution that it is not a casual weight-loss solution but a metabolic treatment requiring careful monitoring.

With its India-specific pricing and strong clinical backing, Mounjaro is set to transform obesity and diabetes care in the country, giving millions a much-needed treatment alternative.